Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Shares Outstanding (Diluted Average) (2016 - 2025)

Cardiff Oncology's Shares Outstanding (Diluted Average) history spans 15 years, with the latest figure at $66.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 40.27% year-over-year to $66.8 million; the TTM value through Dec 2025 reached $66.8 million, up 40.27%, while the annual FY2025 figure was $66.8 million, 40.27% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $66.8 million at Cardiff Oncology, roughly flat from $66.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $66.9 million in Q3 2025 and bottomed at $37.2 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $44.7 million (2023), against an average of $47.8 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) surged 217.69% in 2021 before it grew 0.0% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $39.0 million in 2021, then increased by 11.71% to $43.6 million in 2022, then rose by 2.47% to $44.7 million in 2023, then increased by 6.65% to $47.6 million in 2024, then skyrocketed by 40.27% to $66.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Shares Outstanding (Diluted Average) are $66.8 million (Q4 2025), $66.9 million (Q3 2025), and $66.5 million (Q2 2025).